Do you want to read an article? Please log in or register.
Early predictive factors of visual loss at 1-year in neovascular age-related macular degeneration under anti-VEGF in the GEFAL study
Blindness and Vision ImpairmentMacular Diseases
Related content
Macular Diseases
Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19
Ophthalmol Retina.
Keenan TD, Vitale S, Agrón E, Domalpally A, Antoszyk AN, Elman MJ, Clemons TE, Chew EY, Age-Related Eye Disease Study 2 Research Group.
doi: 10.1016/j.oret.2019.06.001.
Macular Diseases
Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry
Ophthalmology.
Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW 2nd2, Williams GA
doi: 10.1016/j.ophtha.2017.10.010.
Macular Diseases
Characterisation of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents
Ophthalmology.
Nguyen CL, Gillies MC, Nguyen V, Daien V, Cohn A, Banerjee G, Arnold J; Fight Retinal Blindness! Study Group
doi: 10.1016/j.ophtha.2018.11.036.
COMMENTED
Macular Diseases
Insights From Survival Analyses During 12 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration
★ 3
Recommended by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
JAMA Ophthalmol
Fu DJ, Keenan TD, Faes L, Lim E, Wagner SK, Moraes G, Huemer J, Kern C, Patel PJ, Balaskas K, Sim DA, Bunce C, Stratton I, Keane PA
doi: 10.1001/jamaophthalmol.2020.5044
COMMENTED
Macular DiseasesRetinal Diseases
INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Retina.
Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ
doi: 10.1097/IAE.
COMMENTED
Macular Diseases
Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
★ 2
Recommended and commented by
Prof. Dr Stephan Michels, Faculty Member
BMC Ophthalmol.
Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Sakamoto T, Wong TY, Pantiri K, Carrasco J
doi: 10.1186/s12886-020-01554-2.
Macular Diseases
Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial
JAMA Ophthalmol.
Ramakrishnan MS, Yu Y, VanderBeek BL
doi: 10.1001/jamaophthalmol.2019.4577.
RECOMMENDED
Macular Diseases
Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
doi: 10.1016/j.ophtha.2019.11.016.
RECOMMENDED
Macular Diseases
Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration
Acta Ophthalmol.
Aurell S, Sjövall K, Paul A, Morén Å, Granstam E
doi: 10.1111/aos.13989.